Transkaryotic Therapies (TKTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic Therapies (TKTX)

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: paradigm7241 who wrote ()	4/21/2000 1:18:00 AM
From: paradigm7241	of 12

OVERVIEW TKTX's technology focuses on promoter enhanced gene expression/endogenous protein production and gene therapy. In the former area TKTX's lead product is endogenous Epo for the treatment of anemia. It is currently in phase III partnered with Aventis. TKTX is also producing replacement enzymes for patients with Fabry's disease (phase II) and Hunter syndrome. Their major gene therapy target is Factor VIII. Here TKTX stablely transfects autologous fibroblasts from patients with Hemophilia via electroporation with a constitutively active Factor VIII gene. The studies I believe are in phase I/II. TKTX has several products at lower levels of development. To learn more about TKTX go to tktx.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext